Managing Partner
Vesalius BiocapitalCheck size: Vesalius Biocapital does not publish a standard current check-size range on its official site.
Alain Parthoens invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.
Experienced teams translating differentiated science or health technology into products with clear clinical and commercial value.
Opportunities outside life sciences and healthcare, or without credible scientific and development evidence, are less aligned.
Present the science, validation, intellectual property, clinical need, regulatory path, market and financing milestones.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Alain Parthoens is a current Managing Partner at Vesalius Biocapital, according to the firm's official roster. No additional background is inferred where the firm does not publish a biography.